-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Aerovate Therapeutics, Inc gets an overall score of 1/5.
| CurrencyCode | USD |
|---|---|
| ISIN | US0080641071 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | 81.6668 |
|---|---|
| Dividend Yield | 0.0% |
| Market Cap | 78M |
| PE Ratio | None |
| Beta | 0.95 |
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AVTE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
